Status:
COMPLETED
Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with...
Eligibility Criteria
Inclusion
- diagnosis of HCC;
- age ≥ 18 years;
- performance status according to Eastern Cooperative Oncology Group 0-1;
- preserved liver function (Child-Pugh score ≤B7);
- PVTT limited to the first order portal branch.
Exclusion
- any contraindication to TARE treatment;
- macrovascular invasion extended to the main portal trunk and/or to the contralateral portal branch;
- presence of extra-hepatic disease
Key Trial Info
Start Date :
May 8 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04771988
Start Date
May 8 2013
End Date
December 31 2020
Last Update
February 25 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.